This company has been acquired
BELLUS Health Valuation
Is BLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLU (CA$19.5) is trading above our estimate of fair value (CA$16.16)
Significantly Below Fair Value: BLU is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLU?
Other financial metrics that can be useful for relative valuation.
| What is BLU's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$1.87b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 103169.2x |
| Enterprise Value/EBITDA | -17.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does BLU's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.1x | ||
EPRX Eupraxia Pharmaceuticals | 43.1x | n/a | CA$131.8m |
SVA Sernova | 37.2x | 66.5% | CA$141.1m |
ONC Oncolytics Biotech | 4x | 57.5% | CA$116.1m |
BCT BriaCell Therapeutics | n/a | -27.7% | CA$54.3m |
BLU BELLUS Health | 5.1x | 46.1% | CA$2.5b |
Price-To-Book vs Peers: BLU is good value based on its Price-To-Book Ratio (5.1x) compared to the peer average (32.2x).
Price to Earnings Ratio vs Industry
How does BLU's PE Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Book vs Industry: BLU is expensive based on its Price-To-Book Ratio (5.1x) compared to the Canadian Biotechs industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is BLU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 5.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate BLU's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.